European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care
RegulatoryapprovedTECVAYLIdaratumumabPositive
AI Analysis
Summary
Johnson & Johnson announced European Commission approval of TECVAYLI (teclistamab) in combination with daratumumab for relapsed or refractory multiple myeloma, providing a new early treatment option for patients with at least one prior therapy.
Outcome Details
European Commission approved indication extension for teclistamab in combination with daratumumab for relapsed/refractory multiple myeloma in patients with at least one prior therapy
Importance:8/10
Sentiment:
0.85
European Commission approvalindication extensionmultiple myelomacombination therapyregulatory approval
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 21, 2026 9:40 AM